[2-[[2-cyano-3-[4-(diethylamino)phenyl]-1-oxoallyl]oxy]ethyl][3-[[2-cyano-3-[4-(diethylamino)phenyl]-1-oxoallyl]oxy]propyl]dimethylammonium chloride

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Meets generally accepted scientific standards, well documented and acceptable for assessment.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1980

Report date:

1980

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

Single intraperitoneal application of test material at doses of 50, 200 and 700 mg/kg bw followed by a 14-day examination period. Investigation of mortality, clinical signs and body weight development. Gross pathology of sacrificed animals as well as animals that died.

GLP compliance:

no

Remarks:

pre-GLP

Test material

Test material information

Constituent 1

Reference substance name:

preparation containing CAS 78181-99-4

IUPAC Name:

preparation containing CAS 78181-99-4

Details on test material:

Please refer the confidential details on test material

Test animals

Species:

mouse

Strain:

NMRI

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: WIGA
- Weight at study initiation: males 24 - 26 g, females 24 g
- Fasting period before study: 15 h - 20 h before administration
- Diet: Herilan MRH-Haltung; H. Eggersmann KG

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Details on exposure:

Single intraperitoneal application of test material

Doses:

50, 200, 700 mg/kg bw

No. of animals per sex per dose:

5 mice

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 50 - < 200 mg/kg bw

Based on:

test mat.

Remarks on result:

other: 1% significance level

Mortality:

The mortality incidences (sexes combined) were:
700 mg/kg bw: 10/10
200 mg/kg bw: 10/10
50 mg/kg bw: 0/10

For details, see table below

Clinical signs:

700 mg/kg bw: apathy, staggering, twitching, convulsions, exophthalmos, shortness of breath, poor general state
200 mg/kg bw: dyspnoea, apathy, staggering, tremor, cyanosis, exsiccosis, poor general state
50 mg/kg bw: dyspnoea, apathy, staggering, piloerection, poor general state

Body weight:

The animals surviving until the day of scheduled necropsy (low dose group only) showed body weight gain during the study period.
For details, see table below

Gross pathology:

Animals that died: staining of abdominal cavity
Sacrificed animals: slight intraabdominal agglutination

Any other information on results incl. tables

Mortality:

Dose (mg/kg bw)	700	200	50
Males: Number of animals	5	5	5
Dead animals after:
1 h	5	2	0
1 d	5	5	0
2 d	5	5	0
7 d	5	5	0
14 d	5	5	0
Females: Number of animals	5	5	5
Dead animals after:
1 h	5	5	0
1 d	5	5	0
2 d	5	5	0
7 d	5	5	0
14 d	5	5	0

 

Mean weight (g):

Dose (mg/kg bw)		700	200	50
Males: Beginning of test		26	24	24
After	2-4 d			28.6
	7 d			30.4
	13 d			31.4
Females: Beginning of test		24	24	24
After	2-4 d			26.6
	7 d			28.2
	13 d			28.6

 

LD50 determination:

Doses (mg/kg bw)	No. of animals		Dead animals after 14 days	Mortality (%)		Doses used for calculation
50	10		0	0		*
200	10		10	100		*
700	10		10	100
LD50 value		> 50 mg/kg bw			(1% siginificance level)
LD50 value		< 200 mg/kg bw			(1% siginificance level)